You have been successfully logged out.
Gilead’s mission is to advance patient care by developing therapeutics to treat life-threatening diseases.
If you’d like to get in touch with us about any of the content on this site, you can contact us on:
Freecall: 1800 806 112 (within Australia)
Freecall: 0800 443 933 (from New Zealand to Australia)
Email:
For all Gilead Medical Information enquiries, please email [email protected]
For all Kite specific Information enquiries, please email [email protected]
For all transparency enquiries, please email [email protected]
For all media enquiries, please email [email protected]
Adverse Event ReportingAdverse events related to Gilead products should be reported directly to Gilead Australia.
To report an adverse event, please contact Gilead directly on 1800 806 112 (within Australia) or at [email protected].
^TECARTUS® is funded for the treatment of patients with relapsed or refractory mantle cell lymphoma who have received two or more lines of therapy, including a BTK inhibitor (unless ineligible or intolerant to treatment with a BTK inhibitor); and for the treatment of patients with relapsed or refractory CD19-positive B-precursor acute lymphoblastic leukaemia aged 26 years or above, under National Health Reform Act arrangements.
*YESCARTA® is funded for the treatment of relapsed or refractory DLBCL, PMBLC, TFL and HGBCL, following AUTO-SCT or two prior systemic therapies, under the National Health Reforms Act arrangements.
